Biondo Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Biondo Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-261,205	Closed	-$4.25M	–	77
2022 Q1	$4.25M	Sell	261,205 -8,375	-3%	-$134K	0.75%	40
2021 Q4	$3.73M	Buy	269,580 +2,100	+0.8%	+$27.8K	0.62%	43
2021 Q3	$3.84M	Buy	267,480 +1,640	+0.6%	+$25.9K	0.66%	45
2021 Q2	$4.2M	Buy	+265,840	New	+$3.61M	0.72%	45

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Biondo Investment Advisors's BCRX Position: Q2 2022 in Review

Biondo Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 261,205 shares — an estimated $4.25M sold.

Biondo Investment Advisors first reported a position in BCRX in Q2 2021 and held it in 4 quarters. The position peaked at $4.25M in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Biondo Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Biondo Investment Advisors sold 261,205 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $4.25M.
Biondo Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Biondo Investment Advisors's BioCryst Pharmaceuticals position peaked at $4.25M in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Biondo Investment Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.